PR - Resizing - Kaplan Fox Tagline Logo Color.jpg
NAPCO: Kaplan Fox Investigates Potential Securities Fraud at Napco Security Technologies, Inc.
August 22, 2023 15:04 ET | Kaplan Fox & Kilsheimer LLP
NEW YORK, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of NAPCO Security Technologies, Inc. (“NAPCO” or the...
Immatics Final logo (R)_white_background.png
Immatics veröffentlicht Ergebnisse des zweiten Quartals 2023 sowie ein Update zur Geschäftsentwicklung
August 17, 2023 07:00 ET | Immatics N.V.
Klinische Phase-1/2-Studie zur Untersuchung von Immatics‘ zweitem bispezifischen TCR-Programm der nächsten Generation mit verlängerter Halbwertszeit, TCER® IMA402 (Zielstruktur: PRAME),...
Immatics Final logo (R)_white_background.png
Immatics Announces Second Quarter 2023 Financial Results and Business Update
August 17, 2023 07:00 ET | https://immatics.com/
Phase 1/2 clinical trial initiated evaluating Immatics’ second next-generation half-life extended TCR Bispecific program, TCER® IMA402 targeting PRAMEACTengine® IMA203 TCR-T monotherapy against PRAME...
jotul.png
INTERIM FINANCIAL REPORT Q1 2023 - Jøtul AS
May 31, 2023 02:15 ET | Jøtul AS
The Jøtul Group (representing Jøtul AS together with its subsidiaries) is one of the three largest suppliers of fireplaces in Europe and a significant player in North America. The company, with a...
Immatics Final logo (R)_white_background.png
Immatics veröffentlicht Ergebnisse des ersten Quartals 2023 sowie ein Update zur Geschäftsentwicklung
May 16, 2023 07:00 ET | Immatics N.V.
Klinisches Daten-Update von 11 stark vorbehandelten Patienten aus Phase 1b Dosisexpansionskohorte A mit ACTengine® IMA203 TCR-T Monotherapie gegen Zielstruktur PRAME zeigte eine bestätigte objektive...
Immatics Final logo (R)_white_background.png
Immatics Announces First Quarter 2023 Financial Results and Business Update
May 16, 2023 07:00 ET | https://immatics.com/
ACTengine® IMA203 TCR-T monotherapy against PRAME showed 67% confirmed ORR in an interim clinical update on heavily pre-treated 11 patients in Phase 1b dose expansion Cohort A with median duration of...
New logo.png
Connexa Sports Technologies Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q
March 24, 2023 08:30 ET | Connexa Sports Technologies Inc.
Baltimore, March 24, 2023 (GLOBE NEWSWIRE) -- Connexa Sports Technologies Inc. (NASDAQ: CNXA) (www.connexasports.com) (the “Company”) announced that it received a letter from The Nasdaq Stock Market...
Immatics Final logo (R)_white_background.png
Immatics veröffentlicht Ergebnisse des Geschäftsjahres 2022 sowie ein Update zur Geschäftsentwicklung
March 21, 2023 07:31 ET | Immatics N.V.
ACTengine® IMA203 TCR-T-Monotherapie gegen die Zielstruktur PRAME zeigte in einer Zwischenanalyse der klinischen Daten im Oktober 2022 eine bestätigte objektive Ansprechrate (confirmed objective...
Immatics Final logo (R)_white_background.png
Immatics Announces Full Year 2022 Financial Results and Corporate Update
March 21, 2023 07:31 ET | https://immatics.com/
ACTengine® IMA203 TCR-T monotherapy against PRAME showed 50% confirmed objective response rate (cORR) at or above target dose in different solid cancers in an interim clinical update in Phase 1a and...
Stacked-Full-Colour-Logo-(Black) (1) (1) (1) (1).png
Azerion publishes Interim Unaudited Q4 and FY 2022 Results
February 28, 2023 01:00 ET | Azerion Group NV
Delivery on 2022 targets with profitable growth outlook Highlights of Q4 2022 Delivery of 2022 targets. Full year 2022 Net revenue of EUR 453 million (guidance of at...